Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075007 · ClinicalTrials.gov registry record
Brain Vascular Disease in Aging and Dementia
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 48
- Enrollment target
NCT03075007 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 48 participants.
The verdict
NCT03075007 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This study examines the factors that may drive the relationship between vascular disease and Alzheimer's Disease (AD) in a large, longitudinal, multi-ethnic community-based cohort study of older adults in northern Manhattan, New York. In past research, the investigators demonstrated that accumulation of brain vascular disease is associated with risk for development of AD. The study now extends the research to examine how brain vascular disease and AD interact. In this pilot study, the investigators will obtain positron emission tomography (PET) scans to measure amyloid (one of the protein pathological markers of AD) from participants in an ongoing community-based study of aging and dementia (WHICAP). The study will include subjects who are already enrolled in the parent project. Further, this study will enroll both subjects who have never been evaluated with PET scans and those who received a previous baseline PET scan. The study plans to obtain approximately 30 repeat amyloid PET scans and 20 baseline PET scans. The investigators will also conduct transcranial Doppler studies to measure blood flow in the participants with amyloid PET scans. The potential benefits to society should be considerable if this study reveals new information about risk factors for or contributions to AD.
Interventions
- RADIATION Florbetaben F18
- PROCEDURE Transcranial Doppler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2019-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03075007
The ClinicalTrials.gov registry entry for NCT03075007 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Florbetaben F18 is the first listed.
NCT03075007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03075007 about?
NCT03075007 is a clinical study titled "Brain Vascular Disease in Aging and Dementia". This study examines the factors that may drive the relationship between vascular disease and Alzheimer's Disease (AD) in a large, longitudinal, multi-ethnic community-based cohort study of older adults in northern Manhattan, New York. In past research, the investigators demonstrated that accumulatio...
What is the current status of trial NCT03075007?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2017-05-23. Estimated completion is 2019-08-31.
What interventions are being tested in trial NCT03075007?
The interventions under investigation include: Florbetaben F18 (RADIATION), Transcranial Doppler (PROCEDURE).
Who is sponsoring clinical trial NCT03075007?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.